Loading stock data…
GANX
$1.87-0.03 (-1.58%)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gain Therapeutics, Inc. in the Healthcare sector is trading at $1.87. The stock is currently near its 52-week low of $1.41, remaining 14.2% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why GANX maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.87
Potential Upside
5%
Whystock Fair Value$1.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers no...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-108.60%
Volume
Today's trading volume
420,664
Recent News
3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson’s disease, company CEO Gene Mack said during a fireside chat at a Roth Capital Partners conference. The discussion, hosted by Roth managing director and senio
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development
Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc. (NASDAQ:GANX) unveiled new preclinical data on its lead drug candidate, GT-02287. GT-02287, a small molecule, focuses on treating Parkinson’s disease (PD) by restoring […]